475086-75-0

Basic information

• Product Name: SELEXIPAG interMediate
• Synonyms: SELEXIPAG interMediate;4-[(5,6-diphenyl-2-pyrazinyl)(1-methylethyl)amino]-1-Butanol;Selexipag intermediates;1-Butanol, 4-[(5,6-diphenylpyrazinyl)(1-methylethyl)amino]-;1-Butanol, 4-[(5,6-diphenyl-2-pyrazinyl)(1-methylethyl)amino]-;4-[(5,6-Diphenylpyrazinyl)(1-methylethyl)amino]-1-butanol;-[(5,6-diphenyl-2-pyrazinyl)(1-methylethyl)amino]-1-Butanol;4-((5,6-Diphenylpyrazin-2-yl)(isopropyl)amino)butan-1-ol
• CAS NO: 475086-75-0
• Molecular Formula: C₂₃H₂₇N₃O
• Molecular Weight: 361.47998
• EINECS: 1592732-453-0
• Product Categories: non-prostanoid prostacyclin (PGI2) receptor agonist
• Mol File: 475086-75-0.mol
• Article Data: 21

Chemical Properties

• Boiling Point: 514.4±50.0 °C(Predicted)
• Appearance: /
• Density: 1.112±0.06 g/cm3(Predicted)
• Storage Temp.: Sealed in dry,Room Temperature
• Solubility: Chloroform (Slightly), DMSO (Slightly)
• PKA: 15.05±0.10(Predicted)
• CAS DataBase Reference: SELEXIPAG interMediate(CAS DataBase Reference)
• NIST Chemistry Reference: SELEXIPAG interMediate(475086-75-0)
• EPA Substance Registry System: SELEXIPAG interMediate(475086-75-0)

Safety Data

• Hazardous Substances Data: 475086-75-0(Hazardous Substances Data)

Usage

Uses

4-[(5,6-Diphenyl-2-pyrazinyl)(1-methylethyl)amino]-1-butanol is a diphenylpyrazine derivative which belongs to a class of prostacyclin receptor agonists. It is an impurity of Selexipag (S253150) that is a potential drug for the treatment of various vascular disorders such as pulmonary arterial hypertension and arteriosclerosis obliterans.

Upstream product

• 41270-66-0 2-chloro-5,6-diphenylpyrazine 
• 42042-71-7 4-hydroxy-N-isopropylbutan-1-amine 
• 101727-15-5 2-iodo-5,6,-diphenylpyrazine 
• 1689-71-0 2,3-diphenyloxirane 
• 75-26-3 isopropyl bromide 
• 1484-50-0 desyl bromide 
• 119-53-9 2-hydroxy-2-phenylacetophenone 
• 24242-77-1 α-iodo-α-phenylacetophenone 
• 447-31-4 Desyl chloride 
• 39099-23-5 N-isopropyl-N-butylamine 
• 243472-70-0 2-bromo-5,6-diphenylpyrazine 
• 18591-57-6 2,3-Diphenyl-6-hydroxypyrazine 
• 103-29-7 1,1'-(1,2-ethanediyl)bisbenzene 

Downstream Products

• 475084-96-9 2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy}acetic acid tert-butyl ester 
• 475086-01-2 Selexipag 

Relevant articles and documents

Synthesis method of selexipag intermediate

The invention relates to the technical field of medicine synthesis, in particular to a synthesis method of a selexipag intermediate. The preparation method comprises the following steps: reacting a compound as shown in a formula III with 2-aminoacetamidine hydrobromide under the action of a catalyst to obtain a compound as shown in a formula IV; reacting the compound as shown in the formula IV with 4-bromo-1-butanol under the action of alkali to obtain a compound as shown in a formula V; and carrying out N-alkylation reaction on the compound as shown in the formula V under the action of alkali to obtain the selexipag intermediate as shown in the formula I: 4-[(5, 6-diphenylpyrazine-2-yl) (isopropyl alcohol group) amino]-1-butanol. The invention creates a novel synthesis method of the selexipag intermediate, and the method has the advantages of cheap and easily available raw materials, simple operation, mild conditions and high yield.

Synthetic method of selexipag intermediate

The present invention relates to a synthetic method of a selexipag intermediate. The method comprises the following steps: carrying out a nucleophilic substitution reaction on a compound represented by a formula (I) and isopropylamine in an oxygen-free water-free environment in the presence of a hydrogen withdrawing reagent to obtain a compound represented by a formula (II), wherein the structuralformula of the compound represented by the formula (I) is shown in the description, L represents a halogen atom, and the structural formula of the compound represented by the formula (II) is shown inthe description. According to the synthetic method of the selexipag intermediate provided by the invention, in the oxygen-free water-free environment, the compound shown in the formula (I) and the isopropylamine are used as raw materials, the nucleophilic substitution reaction can be performed in the presence of the hydrogen withdrawing reagent to obtain the compound shown in the formula (II), the reaction conditions are mild, the energy consumption is low, the isopropylamine is cheap and easy to obtain, the production costs can be effectively reduced, and the method is suitable for industrial production.

INHIBITORS OF PLATELET FUNCTION AND METHODS FOR USE OF THE SAME

Disclosed herein are small molecule inhibitors of platelet function, and methods of using the small molecules to treat diseases, such as platelet hemostasis and thrombosis. In particular, disclosed herein are compounds of Formula (I) and pharmaceutically acceptable salts thereof: wherein the substituents are as described.